

**PCT**

From the INTERNATIONAL BUREAU

**NOTIFICATION OF THE RECORDING  
 OF A CHANGE**

(PCT Rule 92bis.1 and  
 Administrative Instructions, Section 422)

To:

WALTON, Seán, M.  
 Mewburn Ellis  
 York House  
 23 Kingsway  
 London WC2B 6HP  
 ROYAUME-UNI

Date of mailing (day/month/year) 24 April 1998 (24.04.98)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference SMW/CP5635370	
International application No. PCT/GB97/02108	International filing date (day/month/year) 05 August 1997 (05.08.97)

1. The following indications appeared on record concerning:

the applicant     the inventor     the agent     the common representative

Name and Address QUANTUM BIOSYSTEMS LTD. 12 Pembroke Avenue Denny Industrial Centre Waterbeach Cambridge CB5 9PB United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

the person     the name     the address     the nationality     the residence

Name and Address QUANTUM BIOSYSTEMS LTD., in Creditors' Voluntary Liquidation, acting by its liquidator, ROGER WILLIAM GILLETT of CRANE & PARTNERS Rutland House 44 Masons Hill Bromley, Kent BR2 9EQ United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

the receiving Office     the designated Offices concerned  
 the International Searching Authority     the elected Offices concerned  
 the International Preliminary Examining Authority     other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Eugénia Santos Telephone No.: (41-22) 338.83.38
---	--



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>5</sup> : C12P 21/08, A61K 39/395 G01N 33/574, 33/577, 33/68</p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 90/12885</b> (43) International Publication Date: 1 November 1990 (01.11.90)</p>
<p>(21) International Application Number: PCT/US90/02152 (22) International Filing Date: 20 April 1990 (20.04.90) (30) Priority data: 341,402 21 April 1989 (21.04.89) US (60) Parent Application or Grant (63) Related by Continuation US 341,402 (CIP) Filed on 21 April 1989 (21.04.89) (71)(72) Applicants and Inventors: SAMUEL, John [IN/CA]; 1606 Galbraith House, Michener Park, Edmonton, Alberta T6H 5B5 (CA). LONGENECKER, B., Michael [US/CA]; 8412 118 Street, Edmonton, Alberta T6G 1T3 (CA). STANCZYK-BRZEZINSKA, Grazyna [PL/CA]; 601D Michener Park, Edmonton, Alberta T6H 5A1 (CA). WILLANS, David [CA/CA]; 7 Whitemud Place, Edmonton, Alberta T6H 5X4 (CA). HONORE, Louis, H. [CA/CA]; 12204 39 Avenue, Edmonton, Alberta T6J 0N2 (CA). HAINES, Deborah, M. [CA/CA]; 901 University Drive, Saskatoon, Saska S7N 0J9 (CA). DIENER, Erwin [CA/CA]; 9120 118 Street, Edmonton, Alberta T6G 1T7 (CA). DING, Lei [CN/CA]; 5123 110 Street, Edmonton, Alberta T6H 3C8 (CA).</p>	<p>(74) Agent: COOPER, Iver, P.; Browdy and Neimark, 419 Seventh Street, N.W., Washington, DC 20004 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: MONOCLONAL ANTIBODY FOR DIFFERENTIATION OF SQUAMOUS CELL CARCINOMA ANTIGENS AND METHOD OF USE FOR SAME</p>		
<p>(57) Abstract</p> <p>The invention is a monoclonal antibody (MAb 174H.64) which selectively recognizes antigens associated with squamous cell carcinoma and stem cell populations of stratified epithelium. In well differentiated squamous cell carcinoma tumors, the antibody preferentially binds with the peripheral proliferative compartment of the tumor. The antigens recognized by MAb 174H.64 include cytoskeletal proteins with molecular weight of approximately 48 to 50kD and 57kD. The method of use of the antibody includes diagnosis of squamous cell carcinoma tumours by immunohistology, non-invasive diagnostic imaging <i>in vivo</i>, treatment of squamous cell carcinoma tumours using MAb conjugates of radionuclide or cytotoxic drugs, all immunopurification of SCC antigens.</p>		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

MONOCLONAL ANTIBODY FOR DIFFERENTIATION OF  
SQUAMOUS CELL CARCINOMA ANTIGENS  
AND METHOD OF USE FOR SAME

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a specific binding antibody for differentiation of squamous cell carcinoma antigen and a method for using the monoclonal antibody. Specifically, this invention relates to a murine monoclonal antibody for differentiation of a squamous cell carcinoma antigen of cytoskeletal proteins having molecular weights of 48 to 50 KD and 57 KD and a method for using the monoclonal antibody.

2. Description of the Background Art

G. Kohler and C. Milstein reported a lymphocyte fusion method in their article, "Continuous Cultures of Fused Cells Secreting Antibodies of Preferred Specificity", Nature 265:495 (1975). Their work produced monoclonal antibodies by fusing mouse myeloma tumor cells to spleen cells derived from a mouse that was previously immunized with an antigen. This discovery of antibody production provides a method for unlimited supply of pure antibodies and antibody reagents. These antibodies provide useful tools for cancer diagnosis and therapy.

A multilayered epithelia is found in the epidermis, the mouth and oral cavity, the esophagus, the epiglottis, the larynx, the pharynx, the vagina, and the cervix. These are areas where squamous cell carcinoma and precursor cells of the transformation process are located. Precursor cells are squamous cells, in any stage of transformation, that are

- 2 -

committed to become invasive squamous cell carcinomas. This "pre-SCC stage" is a stage occurring prior to cells being in "frank malignancy" or cancerous cells. The pre-SCC stage includes squamous cells which are morphologically normal, atypia (hyperplasia, metaplasia, hyperkeratosis), significant atypia, dysplasia (mild dysplasia - CIN I, moderate dysplasia - CIN II, and severe dysplasia - CIN III) or carcinoma in situ (CIS). Benign squamous cells in the pre-SCC stage are not committed to become invasive squamous cell carcinomas.

Squamous cell carcinoma (SCC) is a common histological type of cancer of the head and neck, lung, oral cavity, or cervix. Identification and characterization of molecular markers associated with squamous cell carcinoma facilitates earlier diagnosis and treatment of squamous cell carcinomas. Functional studies on squamous cell carcinoma markers can aid in better understanding of the biology of this type of cancer.

Monoclonal antibodies (MAbs) are useful tools as molecular and functional probes for studying tumor associated antigens. The majority of the monoclonal antibodies raised against squamous cell carcinomas are produced by using squamous cell carcinoma cell lines as the immunogen. Antigenic molecules defined by such monoclonal antibodies include cell-surface proteins and cytoskeletal components. Several monoclonal antibodies reacting with squamous cell carcinoma have been reported. However, many of these antibodies either show cross reactivity with other types of cancers or their reactivity is limited to squamous cell carcinomas of certain organs only.

Antibodies have been developed against keratinocytes and their reactivity with squamous cell carcinomas evaluated. A monoclonal antibody produced against human keratinocytes, VM-2, has been reported to selectively bind to the basal layer of the epidermis, as well as squamous and basal cell carcinomas.

- 3 -

This antibody is disclosed in two articles: Morhenn, et al., "A Monoclonal Antibody Against Basal Cells of Human Epidermis: Potential Use in the Diagnosis of Cervical Neoplasia" J. Clin. Invest., 76: 1978-1983, 1985 and Oseroff, et al., "Use of Murine Monoclonal Antibody Which Binds to Malignant Keratinocytes to Detect Tumor Cells in Microscopically Controlled Surgery" J. Am. Acad. Dermatol. 8: 616-619, 1983.

Monoclonal antibodies developed against cytokeratins have been used as probes for studying the keratin expressions in normal and neoplastic epithelia. Cytokeratins exhibit a differentiation-specific pattern of distribution in different layers of stratified epithelium. Specific keratin polypeptides have also been reported as molecular markers for squamous cell carcinoma. Antikeratin MAb's have been proposed as tools for diagnosis of tumors including squamous cell carcinomas.

Antibodies that are known to react with squamous cell carcinoma antigens include MAb's AE1 and AE3, MAb 17.13, and MAb's, PKK1 and PKK2. These antibodies have been described by numerous sources including those identified below. These antibodies fail to differentiate the cytoskeletal proteins with a molecular weight of approximately 48 to 50 kD and 57 kD.

The MAb's AE1 and AE3 are described by: T.T. Sun, et al., J. Invest. Dermatol. 81: 1095 (1983); W. G. Nelson, et al., Cancer Res. 44: 1600 (1984); Hybritech, Inc. (Hybritech), product insert provided with MAb AE1 and AE3; and J. Reibel, et al., Acta Path. Microbiol. Immunol. Scand. Sect. A 93: 323 (1985). The tissue specificity for MAb AE1 is the epidermal basal layer and almost all epithelia. The tissue specificity for MAb AE3 is entire epidermis and all epithelia. MAb AE1 binds squamous cell carcinoma as well as non-SCCs (e.g., adenocarcinoma). No information is available on staining of a squamous cell carcinoma using MAb AE3 alone. MAb AE1 recognizes keratins of acidic type (Mr 40, 50 and 56.5 kD), whereas MAb AE3 recognizes keratins of basic type (58, 52

- 4 -

and 65-67 KD). Hybritech claims "a combination of these two antibodies recognizes almost all known human epithelia keratins." Since these antibodies have a broad spectrum of reactivity towards keratins, they are useful for distinguishing epithelia tissues and their neoplasms from non-epithelial tissues and their neoplasms. However, neither of these antibodies can distinguish "stratified squamous epithelia" and neoplasms derived from them from other types of epithelia (e.g., simple epithelia) and tumors of other epithelia origin.

The MAb 17.13 is described by R. Rankin, et al., Cancer Res. 47: 5684 (1987) and European Patent Application (InTek Diagnostic) Number 87311402.0. (The latter reference summarizes the characteristics of many anti-SCC antibodies.) No characterization of the antigen recognized by this antibody has been reported. The antigen is presumed to be an intermediate type filament, based on electron microscope data. The European patent application states that the antigen is not a cytokeratin. The antibody is specific for basal layer of stratified squamous epithelia. Its reactivity with precancerous lesions of CIN (Stages I-III) is approximately 30% positive. Molecular weight and other characteristics of the MAb 17.13 antigen have not been reported. The SCC-reactivity of MAb 17.13 is homogeneous. The reactivity of MAb 17.13 with animal tissues is unknown.

The MABs PKK1 and PKK2 are described by Holfhofer, et al., Lab. Invest. 49: 317 (1983) and product inserts of LabSystems, Inc. (Chicago, Illinois) for MABs PKK1 and PKK2. These antibodies, respectively, recognize the PKK1 antigen which is a cytokeratin (Mr 41 KD, 45 KD, 48 KD and 56 kD) and the PKK2 antigen for which information is not available. MAB PKK1 binds to all layers of stratified epithelia. PKK2 reportedly (according to Intek) binds to basal and parabasal layers of stratified squamous epithelia as well as columnar epithelium of the normal lung. MAB PKK2 binds to SCCs, but also binds to bronchioalveolar carcinoma. MAB PKK1 binds to

- 5 -

all layers of stratified epithelia and reacts with a broad range of cytokeratins. MAb PKK2 also shows broad reactivity in that it is reactive with normal columnar epithelium (lung) as well as stratified epithelium. Thus, it fails to distinguish stratified squamous epithelia from other types of epithelia. Besides, its tumor reactivity also lacks specificity in that it reacts with lung tumors of nonSCC type.

The art lacks an antibody preparation that is specific for squamous cell carcinoma antigens in many organs and which is useful as a therapeutic and diagnostic agent.

#### SUMMARY OF THE INVENTION

The invention is an antibody preparation which essentially only recognize antigens associated with squamous cell carcinoma (SCC) and stem cell populations of stratified epithelium. Preferably, this preparation comprises monoclonal antibody MAb 174H.64 or a specific binding fragment thereof. The antigens recognized by MAb 174H.64 include cytoskeletal proteins with molecular weights of approximately 48 to 50kD and 57kD.

The invention includes methods for using the antibody, including use for diagnosis of squamous cell carcinoma tumors by immunohistology, immunodetection of circulating SCC antigens in sera, non-invasive diagnostic immunoimaging in vivo, treatment of squamous cell carcinoma tumors using antibodies conjugated to cytotoxic drugs or tagged with a radiosotope, and as a research tool for studying the normal and pathological conditions of stratified squamous epithelium.

The invention includes kits wherein the antibody, antibody preparation, or a method of this invention is used.



- 6 -

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the pattern of MAb 174H.64 binding to squamous cell carcinoma tissues. The peripheral layer of a human anorectal SCC is selectively stained by immunoperoxidase.

Figure 2 compares the specificity of cell killing of the different antibodies and antibody conjugates with DM alone.

Figure 3 illustrates uptake of  $^{125}\text{I}$ -IUdR relative to SCC cells injected.

Figure 4 shows the reduction in uptake as a result of various pretreatments of the SCC cells.

Figure 5 shows the uptake when, after injection of SCC cells into mice, the mice are treated with DM, MAb 174H.64, or a MAb 174H.64-DM conjugate.

Figure 6 illustrates the effect of MAb 174H.64-DM on survival of tumor bearing mice.

Figure 7 is a photograph of a scan of a patient's lung, imaging a metastasis of a cervical carcinoma by means of a MAb 174H.64-DM conjugate.

DETAILED DESCRIPTION OF THE INVENTION

The invention includes antibody preparations. The term "antibody preparations" encompasses whole antibodies according to this invention as well as specific binding fragments of such antibodies. An antibody or antibody fragment according to this invention can be conjugated to another substance. Such substances include labels (including, without

- 7 -

limitation, radioisotopes, enzymes, co-enzymes, enzyme inhibitors, fluorophores and fluorescence quenchers), cytotoxic drugs such as daunomycin, and macromolecular chromatographic supports. The antibody preparation may be monoclonal or polyclonal, but if polyclonal it is essentially monospecific for squamous cell carcinomas and stem cell populations of the squamous epithelium. Use of monoclonal antibodies is preferred.

The invention includes a murine monoclonal antibody for differentiation of squamous cell carcinoma antigens and a method for using the monoclonal antibody. The monoclonal antibody of this invention selectively or, essentially, only recognizes antigens associated with squamous cell carcinoma and stem cell populations of stratified epithelium. The antibody, in well-differentiated squamous cell carcinoma tumors, preferentially binds with the peripheral proliferative compartment of the tumor. The antigens recognized by the monoclonal antibody of this invention include cytoskeletal proteins with molecular weights of approximately 48 to 50kD and 57kD. The potential applications of the antibody include diagnosis of squamous cell carcinoma tumors by immunohistology, noninvasive diagnostic imaging in vivo. treatment of squamous cell carcinoma tumors using monoclonal antibodies conjugates of radionuclide or cytotoxic drugs, and as a research tool in studying the normal and pathological conditions of stratified squamous epithelium. The monoclonal antibody, though raised against Tn-HSA, does not demonstrate any reactivity with this non-SCC immunogen and demonstrates a high degree of selectivity towards squamous cell carcinoma tissues.

The preferred monoclonal antibody of this invention is designated MAb 174H.64. The description of this invention shall refer primarily to this preferred monoclonal antibody. The reference to the preferred embodiment of the invention in this description is not intended to exclude essentially equivalent variations of the preferred monoclonal antibody from

- 8 -

the invention. The organ of origin can include the mouth and oral cavity, the esophagus, the epiglottis, the larynx, the pharynx, the vagina, and the cervix.

MAb 174H.64 selectively binds with human squamous cell carcinoma (100% in the inventors' studies) irrespective of the organ of origin. This antibody does not bind with tumors derived from simple epithelia or tumors of non-epithelial origin. This squamous cell carcinoma-specific reactivity of the antibody extends to spontaneous SCC-like tumors of other mammals including cows, dogs and cats. No data is available for the reactivity of MAb 17.13 and VM-2 with animal tumors.

MAb 174H.64 selectively binds with a stem cell population (basal and parabasal layers) of normal human stratified squamous epithelium. The antibody also shows selective reactivity with thymic epithelium and myoepithelial cells of breast ducts. The antibody does not bind with simple epithelia or non-epithelial tissues. This suggests that MAb 174H.64 recognizes a differentiation antigen characteristic of stem cell populations of stratified squamous epithelia. MAb 17.13 and VM-2 also show selective reactivity with the basal layer of stratified squamous epithelium. MAb 17.13 has also been reported to be reactive with myoepithelial cells of human breast ducts. No data is available for the reactivity of these two antibodies with thymic epithelium and for the reactivity of VM-2 with myoepithelial cells.

Squamous cell carcinoma tumors with high degree of differentiation show preferential binding of the antibody towards the peripheral layer of the tumor comprised of highly proliferative primitive cells. The more differentiated cells, towards the center of the tumor show little or no staining with the antibody. This observation suggests that the epitope recognized by MAb 174H.64 is characteristic of the proliferative compartment of the squamous cell carcinoma and is not expressed by the more differentiated squamous cell

- 9 -

carcinoma tumor cells. This is surprising in that it is believed that no other monoclonal antibody has such selective reactivity towards the proliferative compartment of squamous cell carcinoma. This characteristic can provide a valuable diagnostic and therapeutic utility for the invention.

MAb 174H.64 shows a unique pattern of staining with normal human cervix. The reactivity of MAb 174H.64 with basal and parabasal layers of mature squamous epithelium is 97 and 81%, respectively, whereas the reactivity is reduced to about 73 and 59%, respectively, in immature squamous epithelia. The subcolumnar (reserve) cells of the cervix show a reactivity of 70%. These results suggest that the differentiation antigen recognized by MAb 174H.64 is also a marker for epithelia maturation in the cervix.

MAb 174H.64 shows binding with premalignant lesions. In cervical intraepithelial neoplasia (CIN) 69% of the cases showed reactivity with basal layer and 54% of the cases showed reactivity with parabasal layer. In kilocytotic atypia (KA) all of the cases tested showed reactivity with the antibody.

The antigens recognized by MAb 174H.64 are two cytoskeletal proteins with approximate molecular weights of 48 to 50kD and 57kD. These molecular weights, although suggestive of human cytokeratins #14 and #5 which are markers for non-keratinizing stratified squamous epithelium, are different since the cytokeratins #14 and #5 are distributed also in suprabasal layers.

The monoclonal antibody of this invention can be useful as a diagnostic reagent, a therapeutic agent for squamous cell carcinoma tissue, and a research tool. The highly selective reactivity of MAb 174H.64 can be used as a reagent for unambiguous diagnosis of squamous cell carcinomas irrespective of the tissue of origin. This diagnostic utility can include immunohistological diagnosis, diagnostic imaging,

- 10 -

and serodiagnosis. The therapeutic utility can include specific use as a target cytotoxic drug. The research utility can include numerous uses regarding cell studies and therapeutics. The antibody may also be used in the immunopurification of SCC-associated antigens. The purified antigens may be used to raise monospecific monoclonal or polyclonal antibodies for use as taught herein.

MAb 174H.64 can be used as a reagent for histological typing of tumors in frozen sections. For example, the diagnosis of adenosquamous carcinoma of cervix can be difficult with respect to ascertaining whether undifferentiated areas are of squamous or glandular derivation. A positive staining with MAb 174H.64 can resolve this problem, which may be difficult even with electron microscopy. For such diagnostic purposes, any labeling technique suitable for histological use may be employed, including but not limited to radiolabels, fluorophores, enzymes, and ferritin. The labeling may be direct or indirect (e.g., via an avidin-biotin, protein A-F<sub>c</sub>, or antibody -F<sub>c</sub> bridge).

MAb 174H.64 can be used for diagnostic imaging of squamous cell carcinoma. Unambiguous diagnosis of squamous tumors based on selective in vivo localizations of radiolabelled MAb 174H.64 can be especially valuable for the following applications. This procedure can determine that location, size, and extent of the invasion of the primary tumor. It can track the metastatic spread of the tumor and detect small metastatic areas in lymph nodes or organs, thus preventing the need for exploratory surgery. The procedure provides non-invasive determination of the histogenesis of a tumor. It can also provide a noninvasive monitoring of the response of the tumor to treatment. The localization of the monoclonal antibody in a tumor, that is necessary for use in diagnostic imaging, is demonstrated in Table 1. The acutal imaging of a tumor is set forth in Example 3.

- 11 -

TABLE 1

Biodistribution of  $^{125}\text{I}$  - 174H64 and  $^{131}\text{I}$  - MOPC-21 (isotype matched control antibody) in normal and tumor bearing (KLN-205 a murine squamous cell carcinoma) lung of DBA2 mice 72h after the injection of the antibodies.

	% Injected dose/g tissue		% Injected dose in the organ	
	174H.64	MOPC-21	184H.64	MOPC
Tumor Bearing Lung	7.7 $\pm 0.99$	1.6 $\pm 0.51$	5.4 $\pm 2.85$	1.16 $\pm 0.97$
Normal Lung	5.5 $\pm 0.209$	1.9 $\pm 1.3$	0.94 $\pm 0.062$	0.34 $\pm 0.24$

Serodiagnosis can be performed, if the antigens detected by MAb 174H.64 are shed into serum. Detection is then possible by the ability of the serum to bind the monoclonal antibodies using ELISA, RIA or other immunoassay techniques. This principle can also be extended, as a diagnostic tool, to detection of the antigen shed into urine in bladder squamous cell carcinomas, or of antigen shed in other biological fluids as appropriate.

The monoclonal antibody of this invention can provide specific therapy for squamous cell carcinoma. The monoclonal antibody in such therapy can be used alone, or to deliver a cytotoxic or radiolabelled conjugate to the target SCC cells. Studies with a daunomycin conjugate of this antibody demonstrate the conjugate's ability to kill a murine squamous cell carcinoma cell line in a selective fashion. Tables 2 and 3 demonstrate this therapeutic utility.

- 12 -

TABLE 2

Hematopoietic reconstitution of lethally irradiated DBA2J mice with syngeneic bone marrow from which contaminating KLN-205 squamous cell carcinoma cells had been purged with a target-specific immunoconjugate (174H.64 - Daunomycin)

Treatment Groups	cpm in Lung means $\pm$ SD
bone marrow only	1,372 $\pm$ 449
bone marrow + KLN-205 (untreated)	29,336 $\pm$ 4,505
bone marrow + KLN-205 (DM treated)	11,065 $\pm$ 6,144
bone marrow + KLN-205 (antibody treated)	29,197 $\pm$ 2,490
bone marrow + KLN-205 (immunoconjugate treated)	4,207 $\pm$ 2,121

A mixture of  $1 \times 10^6$  DBA2J bone marrow cells and  $1 \times 10^6$  KLN-205 cells was treated in vitro for 2 hours at 4°C washed and injected into each of 850 rad irradiated recipients. Twenty-five days later, lungs were tested for  $^{125}\text{I}$ -IUdR incorporation by injecting 2  $\mu\text{Ci}$  of  $^{125}\text{I}$ -IUdR and counting the lungs for  $^{125}\text{I}$  14 h after the injection. The concentration of the immunoconjugate was adjusted to contain 10 $\mu\text{g}/\text{ml}$  of DM.

TABLE 3

Effect of MAb 174H.64 Daunomycin (DM) conjugate in vivo treatment, as the KLN-205 SCC tumor growth in DBA27 mice.

Group	Number of Animals	CPM( $^{125}\text{I}$ -IUdR Uptake)
Normal	4	8.038 $\pm$ 3,471
174H.64 Daunomycin Conjugate	5	32,668 $\pm$ 20,354
Untreated	3*	108,464 $\pm$ 82,570

\* Two of the untreated mice died on day 30 of the experiment and had extensive tumor spread in the lung.

\* KLN-205 ( $10^6$  cells) were injected into DBA2 male mice and were divided into two groups (5 mice each) Five of the above mice each were injected with MAb 174H.64-DM (100 $\mu\text{g}$  DM, 1.8 mg of MAb, on the 5th and the 10th days after the injection of KLN-205 cells. On the 34th day 2  $\mu\text{Ci}$  of  $^{125}\text{I}$ -IUdR was injected intravenously to each mice and lungs were taken out and counted in a gamma counter.

The present invention is not limited to the use of a particular cytotoxic drug, though daunomycin is preferred. Other cytotoxic drugs known to be effective against cancer

- 13 -

cells include ricin. Nor is it limited to any particular method of conjugating the cytotoxic drug to the antibody, though use of an acid-sensitive cis-aconityl spacer is preferred.

MAB 174H.64 can be labelled with radionuclides such as  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{90}\text{Y}$ ,  $^{211}\text{At}$ ,  $^{67}\text{Cu}$ , and  $^{186}\text{Re}$  and used to deliver therapeutic doses of radiation selectively to the squamous cell carcinoma tumor tissue. For the purpose of the appended claims, reference to the antibody as being associated with a cytotoxic agent is intended to include antibodies labeled with a therapeutic radionuclide. MAB 174H.64 can be used for imaging when labelled with radionuclides such as  $^{99}\text{Tc}$ ,  $^{111}\text{In}$ , and  $^{67}\text{Ga}$ . The present invention is not limited to use of a particular radionuclide or radiolabeling technique.

The monoclonal antibody of this invention can be used as a research tool as follows. Expression of the cytoskeletal proteins can be detected by MAB 174H.64 during differentiation of the normal stratified epithelium and used to establish its functional significance. Evaluation can be performed of premalignant lesions of uterine cervix such as CIN and KA. This monoclonal antibodies binds with 69% of basal CIN and all of KA tissue samples tested. Clinical and therapeutic significances of positivity and negativity can be determined by careful clinical and pathological follow up. The prognosis of the lesion can be defined in terms of negativity or grades of positivity to this antibody. The monoclonal antibody can be used to study the biology of squamous cell carcinoma with respect to expression of the antigen during transformation, progression, and differentiation of the tumor.

The monoclonal antibody of this invention can be made and used according to the following example. A hybridoma cell line secreting MAB 174H.64 was deposited under the Budapest Treaty on April 18, 1989 at the American Type Culture Collection (ATCC), Rockville, Maryland, and has received the



- 14 -

designation ATCC HB 10105. The deposit of this cell line should not be construed as a license to recipients to use the cell line.

Example 1: Preparation and Characterization of MAb 174H.64

The example is of the preferred embodiment of the invention. The preferred embodiment of the invention is the monoclonal antibody designated MAb 174H.64. The following procedure represents the best mode for deriving and testing the monoclonal antibody of this invention. The comparative data are provided for comparison purposes to demonstrate certain unexpected and desirable characteristics of the invention.

Immunization and hybridoma production

RBF/Dn mice were immunized by two consecutive i.p. injections, one week apart, of a mixture of human chorionadotrophin (HCG, 50 µg) and a synthetic carbohydrate conjugated to human serum albumin. This conjugate (Tn-HSA) is N-acetyl galactosamine alpha-linked to human serum albumin at a ratio of 40 residues per molecule of carrier (50 µg) in complete Freund's adjuvant. On the 12th day they were given another i.p. injection of a mixture of HCG (400 µg) and Tn-HSA (400 µg) in phosphate-buffered saline (PBS, contains 140 mM NaCl, 2.68mM KCl, 8.1 mM Na<sub>2</sub>HP0<sub>4</sub>.2H<sub>2</sub>O, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.2). On 13th day they were further immunized by an i.v. and an i.p. injection, each consisting of a mixture of HCG and Tn-HSA (200 µg each). The latter procedure was repeated on the 14th day. On the 15th day, the spleen cells from mice having high antisera titres against HCG and Tn-HSA were fused with FOX-NY cells (Hyclone Lab., NY). Hybrids with positive reactivity against Tn-HSA and negative reactivity with HSA were selected and recloned. The supernatants from the reclones were tested for reactivity against tumor tissues by immunohistological

- 15 -

staining. A reclone designated 174H.64 showed strong and selective reactivity with human squamous cell carcinomas, although it did not show any reactivity with Tn-HSA. This hybridoma (double recloned) was chosen for further studies based on its selective reactivity with squamous cell carcinoma tissues.

### Isotyping

MAb 174H.64 was isotyped using a Mouse Type Isotyping Kit (Biorad Laboratories, Mississauga, Ontario, Canada) by an enzyme immunoassay (EIA) method. A microtitre plate was coated with the antibody by an overnight incubation of 4°C of the culture supernatant of the hybridoma grown in serum free medium. The microtitre wells were serially incubated with bovine serum albumin (1%) in PBS for 30 minutes at 37°C, isotyping reagent (rabbit anti mouse Ig subtypes) for two hours at room temperature, and goat anti rabbit IgG conjugated with horseradish peroxidase (HRP) for 1 hour at room temperature. After each of the above steps, the plate was washed with PBS. Finally, the microtitre wells were incubated with HRP substrate solution for 30 minutes at room temperature and the optical density read by an EIA reader.

### Purification of 174H.64.R24; Radiolabelling and Biotinylation

Ascitic fluids were produced by injection of hybridoma 174H.64 cells ( $2 \times 10^5$ ) i.p. into pristane-primed Balb/c mice. The antibody was purified by a two step procedure involving ammonium sulphate (50%) precipitation and protein A sepharose column chromatography. The purified antibody fraction contained a single protein band on cellulose acetate electrophoresis and was immunoreactive on squamous cell carcinoma frozen sections as shown by immunoperoxidase staining.

- 16 -

The antibody was radioiodinated by the iodogen method. Purified MAb 174H.64.R24 (50  $\mu$ g) in phosphate buffered saline (PBS, 50  $\mu$ g) was mixed with "no carrier added" Na  $^{125}$ I (500 Ci) in PBS (10  $\mu$ l) and was transferred into a borosilicate glass tube coated with iodogen (2  $\mu$ g) at the bottom. The reaction was allowed to proceed at room temperature for 2 minutes and the solution was then transferred into another tube containing 0.05% KI in PBS (100/ $\mu$ l) and allowed to equilibrate for 3 minutes the antibody was separated from inorganic iodide using a Biogel P-100 spun column.

MAb 174H.64 was biotinylated according to a known, reported procedure. A solution of MAb 174H.64 (2 mg) in PBS (400  $\mu$ l) was mixed with 0.2 M sodium bicarbonate solution containing 0.15 M potassium chloride pH 8.1. To this a solution of Biotin-LC-NHS (125  $\mu$ g, Pierce) in PBS (25  $\mu$ l) was added and incubated at room temperature for 20 minutes. The reaction was stopped by addition of 1 M ammonium chloride solution pH 6.0 (50  $\mu$ g) and the solution was extensively dialyzed against PBS.

#### Cell Lines

All the squamous cell carcinoma cell lines were obtained from American Type Culture Collection, Rockville, Maryland, and grown in RPMI containing 10% fetal calf serum (FCS) and gentamicin (40 units/ml). Normal human keratinocytes were obtained from Clonetics Corporation, San Diego, CA, and were cultured in serum free keratinocyte growth medium (Clonetics Corporation).

- 17 -

Isolation of mouse epidermal keratinocytes

Epidermal keratinocytes were isolated from neonatal (1 day old) ICR mice according to a known, reported procedure. Briefly, mice were decapitated, skin was removed and washed in Hanks balanced salt solution (HBSS). The skin was then placed dermal side down in HBSS containing trypsin (0.025%) EDTA (0.02%) and incubated at 37°C for 1 hour. The trypsin EDTA solution was aspirated and replaced with RPMI with 10% FCS. The epidermis was then gently separated from the dermis using forceps and agitated gently in the medium. The resulting cell suspension was then separated from the epidermal and dermal layers and washed 2 times with RPMI followed by PBS. This cell suspension was used for immunoperoxidase staining.

Immunohistology

Tumor tissues for immunohistological studies were embedded in OCT, frozen in isopentane and stored at 70°C. Immunoperoxidase staining of frozen sections or cell smears were done according to the avidin-biotin peroxidase complex (ABC) method that is known in the art. Frozen sections of 8 um were cut on a cryostat and mounted on poly L-lysine (PLL) coated glass slides. The cell smears were prepared from a single cell suspension of cells using PLL coated glass plates and were air dried. The glass slides were then serially incubated with primary antibody (174H.64) for 15 minutes, with 0.02% glutaraldehyde for 5 minutes at 4°C, with biotinylated secondary antibody (antimouse IgG) for 30 minutes, and with ABC reagent for 20 minutes. After each of the above steps, the slides solution containing 0.5% hydrogen peroxide for 5 minutes, washed in water, counterstained with hematoxylin and mounted in permount. A brown color in the cells corresponds to positive reaction with the antibody. Whenever mouse tissues were stained by the above procedure, a biotinylated primary antibody was used and the step with the antimouse IgG was

- 18 -

omitted. An isotype matched mouse myeloma protein (MOPC-21) was used as a negative control antibody in all immunoperoxidase staining.

#### Reactivity of MAb 174H.64 With Cancer Tissues

Frozen sections of human cancer tissues of various origins were tested for reactivity with MAb 174H.64 by immunoperoxidase staining by the ABC method. An isotype matched control antibody (MOPC-21) was used as a negative control. The results of these studies are summarized in Table 4.

TABLE 4

The binding of MAb 174H.64 with frozen sections of human tumors of various origins.

Tumor	Number Tested	Number Positive
Squamous cell Carcinoma		
Lung	36	36
Skin	9	9
Tongue	1	1
Uterine Cervix	4	4
Nasopharynx	2	2
Larynx	3	3
Penis	1	1
Vulva	2	2
Anus	2	2
Lip	2	2
Non-Squamous Lung Carcinomas (Adeno, Small Cell and Large Cell)	7	0
Adeno Carcinoma		
Breast <sup>a</sup>	10	0
Colon	7	0
Ovary	15	0
Prostate	1	0

TABLE 4 (Continued)

The binding of MAb 174H.64 with frozen sections of human tumors of various origins.

Tumor	Number Tested	Number Positive
Non Salivary Gland Biphasic Malignancies with Squamous Component		
Adenocarcinomata with Admixed Mature Squamous Component, "Adenoacanthoma" of Endometrium	3	3 (squamous Component only)
Adenocarcinoma with Malignant Squamous Component, Adeno-squamous Carcinoma of Pancreas	1	1 (squamous Component only)
Carcinosarcoma with Squamous Epithelial Component, Pulmonary Carcinosarcoma	1	1 (squamous Component only)
Biphasic Malignancies of Salivary Glands		
Mucoepidermoid Carcinoma	1	1 (Component of Squamoid cells that are of myoepithelial origin)
Adenoid Cystic Carcinoma	1	1 (Cell populations, often about "pseudo-cysts," believed to be of myo-epithelial origin and having some squamous features by electron-microscopy)

TABLE 4 (Continued)

The binding of MAb 174H.64 with frozen sections of human tumors of various origins.

Tumor	Number Tested	Number Positive
Transitional Cell Carcinoma		
Bladder	1	0
Benign Tumors		
Ovary	10	0
Breast	5	0
Squamous Mucosa	2	2(basal cell only)
Melanocytic Nevi	6	0
Salivary Tumours	3	3(Biphasic - only myo-epithelial cells stained)
Thymoma	1	1(Epithelial Component only)
Other Carcinomas		
Kidney	2	0
Lymphomas		
B Cell Lymphoma	10	0
Hodgkins	2	0
Sarcomas		
Miscellaneous Soft Tissues	4	0
Melanomas		
Cutaneous	5	0

\* The myoepithelial cells of breast ducts were positive.

MAb 174H.64 showed selective binding with all human squamous cell carcinomas tested irrespective of the organ or origin, for a variety of other histological type of tumors. Figure 1 shows the pattern of MAb 174H.64 binding to squamous cell carcinoma tissues with preferential binding of the antibody to the peripheral layer of the tumor. The normal tissues adjacent to the tumor showed no binding with the

antibody. Several spontaneously arising tumors from other mammals were also studied for their reactivity against MAb 174H.64 and the results are summarized in Table 5.

TABLE 5

The binding of MAb 174H.64 with frozen section of non-human tumors.

Tumor	Number Tested	Number Positive
Canine Tumors		
Squamous/Basal Cell Carcinomas	10	10
Other carcinomas	14	0
Benign basal cell tumors	4	4

TABLE 4 (Continued)

The binding of MAb 174H.64 with frozen sections of human tumors of various origins.

Tumor	Number Tested	Number Positive
Canine Tumors (cont'd)		
Papillomas <sup>a</sup>	4	4
Perianal adenoma <sup>a</sup>	2	2
Other benign epithelia tumors	5	0
Mesenchymal tumors	45	0
Bovine Squamous Cell Carcinoma	4	4
Feline Squamous Cell Carcinoma	2	2

<sup>a</sup> In papillomas and perianal adenomas only the basal cell population showed staining with the antibody.

Canine squamous and basal cell carcinoma tissues showed selective binding with the antibody while other carcinomas and tumors of mesenchymal origin did not show any reactivity. The reactivity of the antibody was also observed for bovine and feline squamous cell carcinomas. In the staining of a well-differentiated metastatic bovine lung squamous cell carcinoma, we observed increased antibody binding to the peripheral tumor cells. Among the benign epithelia tumors of dogs, basal cell tumors showed homogeneous staining, whereas in papillomas and perianal adenomas, the staining was limited to basal cells only.



Reactivity of MAb 174H.64 With Normal Tissues

Normal human tissues were studied for their reactivity with MAB 174.64 and the results are summarized in Table 6. Highly selective reactivity was observed for the basal cells of the stratified epithelium, thymic epithelium, and myoepithelial cells around breast ducts. No reactivity was observed for non-stratified epithelium (e.g., colon) or tissues of non-epithelial origin.

TABLE 6

The binding of MAb 174H.64 with frozen sections of normal human tissues.

Tissue	Number Tested	Number Positive	Cells Staining (primarily Cell Cytoplasm Positivity unless Indicated Otherwise)
Colonic mucosa	6	0	
Heart	1	0	
Liver	3	0	
Ovary	7	0	
Fallopian Tube	2	0	
Breast	14	14	Duct myoepithelial cells only
Endometrium	10	0	
Endocervix	25	0	Subcolumnar cells in continuity with basal cells can be positive under special circumstances
Connective Tissues	40	0	
Skeletal Muscle	3	0	
Thyroid	4	0	
Parathyroids	1	0	

TABLE 6 (Continued)

The binding of MAb 174H.64 with frozen sections of normal human tissues.

Tissue	Number Tested	Number Positive	Cells Staining (primarily Cell Cytoplasm Positivity unless Indicated Otherwise)
Epidermis	5	5	(Basal and parabasal cells b**
Exocervix	25	25	Basal and parabasal cells b**
Other Squamous Mucosa	15	15	Basal and parabasal cells
Respiratory mucosa including			
Bronchial mucosa	15	0	
Other Lung Tissues	12	0	
Transitional Epithelium	5	0	

TABLE 6 (Continued)

The binding of MAb 174H.64 with frozen sections of normal human tissues.

Tissue	Number Tested	Number Positive	Cells Staining (primarily Cell Cytoplasm Positivity unless Indicated Otherwise)
Kidney	4	0	
Brain	3	0	
Prostate	2	0	
Pancreas	2	2	Duct myoepithelial cells
Salivary Glands	5	5	Duct and lobular myoepithelial cells
Thymus	3	3	Thymic epithelial cells with prominent filaments extending along outer rim of thymic cortex and within central thymic medullary regions a*

a\* The only normal human cell with significant cell membrane accentuation on 174H64 immunostaining, and significant accentuation of greatly elongated cell processes is the thymic epithelial cell.

- 24 -

b\*\* In inflammation of squamous epithelium, significant cell membrane accentuation on 174H64 immunostaining, and significant accentuation of elongated cell filamentous processes, is seen on isolated scattered intraepithelial anucleate dendritic cells, presumably of keratinocyte origin. In addition, extracellular pools containing 174H64 filamentous deposits, located between viable nonreactive keratinocytes, are found in inflamed, especially virally inflamed, squamous epithelium.

The reactivity of the antibody with the basal layer of the stratified epithelium was also demonstrated on bovine and mouse skin. A mouse keratinocyte suspension enriched in basal cells was prepared by trypsin dissociation of the neonatal mouse skin. A cell smear of this suspension on immunoperoxidase staining showed 30 to 50% of the cells to be positive for their reactivity with the antibody. A normal human keratinocyte culture having basal cell characteristics demonstrated all cells to be positive for their reactivity with the antibody.

#### Reactivity of MAb 174H.64 With SCC Cell Lines

While as previously stated, MAb 174H.64 was reactive with all SCC tissue sections tested, several human squamous cell carcinoma cell lines (SCL-1, SIHAA, ME 180, C-33A) were tested for their reactivity with the antibody by cell smear immunoperoxidase staining and were found negative. In contrast, a murine metastatic lung squamous cell carcinoma cell line (KLN-205) was reactive with the antibody.

#### Reactivity of MAb 174H.64 with Squamous Cell Carcinoma Animal Model

KLN-205 cells ( $10^6$ ) were injected i.v. into 8 week old DBA/2 male mice by a method standard in the art. The lungs, dissected from these mice after 21 days, showed extensive tumor colony formation. This tumor on immunoperoxidase staining showed strong reactivity with the antibody and preferential staining of the cells in the

- 25 -

periphery of the tumor. Adjacent normal tissues as well as the lung tissue from a normal mouse did not show any binding with the antibody.

#### Characteristics of the antigen

Protein extracts were prepared from a bovine metastatic lung squamous cell carcinoma tumor, a human lung squamous cell carcinoma tumor, a human ovarian adenocarcinoma tumor, and normal human epidermal keratinocytes grown in vitro as follows. The tissue samples or cell pellets were homogenized with 10 volumes of a Nonidet P-40 (NP-40, Sigma Chemical Company) extraction buffer (1% NP-40, 2 mM EDTA, 1 mM penyl methyl sulphonyl fluoride, 2 mM pepstatin 10 mM o-phenanthrolin, and 150 mM NaCl in 50 mM Tris HCl buffer pH 7.5) at 4°C for 30 minutes and then centrifuged at 100,000g for 1 hour. The residue was again extracted using 10 volumes of sodium dodecyl sulfate (SDS) extraction buffer (2% SDS and 10 mM 2mercaptoethanol in 10 mM Tris HCl buffer pH 7.5) at room temperature for 10 minutes, boiled at 100°C for 10 minutes, and then centrifuged at 10,000g for 15 minutes. The proteins in these extracts were separated on a discontinuous gradient SDS-poly acrylamide gel electrophoresis (4% stacking gel and a 4% to 15% gradient resolving gel) under standard reducing conditions. After electrophoresis, the gel was incubated in 200 mL of protein refolding buffer (4 M urea, 2 mM EDTA, 50 mM NaCl, 0.1 mM dithiothreitol in Tris HCl pH 7.5) for 18 hours with one change of buffer at room temperature and then equilibrated in transfer buffer (190 mM glycine in 25 mM Tris HCl pH 8.8) at 4°C for 1 hour. The proteins were electrophoretically transferred from the gel to a nitrocellulose membrane (Biorad) at 180 mA at constant current for 18 hours. The nitrocellulose sheets were removed, incubated in the blocking buffer containing 3% gelatin in PBS for 1 hour and washed twice in TPBS (PBS containing 0.05% Tween 20) for 5 minutes. They were then incubated with <sup>125</sup>I labelled

- 26 -

antibodies ( $5 \times 10^5$  cpm/mL) in antibody buffer (TPBS containing 1% gelatin) for 2 hours and washed 6 times in TPBS for 5 minutes each. The nitrocellulose sheets were air dried and exposed to Xray film at  $-70^\circ\text{C}$ . The immunoblots of the NP-40 extracts of the above tissues and the SDS extracts of adenocarcinoma showed no binding with  $^{125}\text{I}$  labelled MAb 174H.64, while the immunoblots of the SDS extracts of bovine squamous cell carcinoma, human squamous cell carcinoma and human keratinocytes showed selective binding of  $^{125}\text{I}$  labelled MAb 174H.64 with specific protein bands. The immunoreactive protein bands in the keratinocyte SDS extract were of approximate molecular weight of 48 to 50kD (possibly a doublet) and 57kD. The bovine and human squamous cell carcinoma SDS extracts showed only one prominent band each with the approximate molecular weight of 48 to 50kD for the former and 57kD for the latter. A control antibody (155H.7) failed to bind with any of the above tumor extracts.

Reactivity of MAb 174H.64 with normal and premalignant epithelium of cervix

Frozen sections of normal and premalignant epithelium of cervix were examined for binding with MAb 174H.64. The results are summarized in Tables 7 and Table 8.

- 27 -

TABLE 7

Reactivity of MAB 174H.64 with normal epithelium of cervix.

Epithelium	No positive/no tested	% positive
Mature stratified epithelium		
Basal layer	36/37	97.3
Parabasal layer	30/37	81.1
Immature stratified epithelium		
Basal layer	51/70	72.9
Parabasal layer	41/70	58.5
Subcolumnar epithelium	8/16	50

TABLE 8

Reactivity of MAb 174H.64 with premalignant lesions of cervix.

Preneoplastic lesion	No positive/no tested	% positive
Cervical Intraepithelial neoplasia (CIN)		
Basal layer	36/52	69.2
Parabasal layer	28/52	53.9
Koilocytotic atypia	16/16	100

In mature and immature squamous epithelium of the normal cervix, the staining was limited to basal and parabasal layers only. In the mature epithelium virtually 100% of the basal and parabasal layers were stained whereas in the immature epithelium the staining was limited to a range between 71 and 73%. In the subcolumnar epithelium in 70% of the cases staining could be observed for the reserve cells. These results suggest that the expression of this antigen is acquired during the process of maturation of the epithelium and is lost while the stem cells of the mature epithelium undergoes differentiation. The staining pattern of the reserve cells can reflect the proportion of cases where reserve cells are committed to become the stem cells of the stratified epithelium.

- 28 -

Example 2: Immunotherapeutic Use of MAb 174H.64

MAb 174H.64, which selectively recognizes an epitope expressed on the proliferating cells of mammalian squamous carcinomas (Sq Ca), was covalently coupled to daunomycin (DM) by an acid sensitive linker and tested for its selective cytotoxicity for Sq Ca. A murine lung Sq Ca model for chemoimmunotherapy using MAb 174H.64-DM conjugates was developed. This model utilizes the KLN-205 Sq Ca cell line which metastasizes to the lungs following i.v. injection and shows a pattern of growth similar to those of spontaneous Sq Ca, that is, characterized by highly proliferative cells at the periphery of the tumor (reactive with 174H.64) with the keratinized differentiated cells toward the center (not reactive with 174H.64). MAb 174H.64-DM conjugates showed marked and specific cytotoxicity against KLN-205 cells both in vitro and following i.v. injection of the immunoconjugate in mice with established lung metastases. The conjugate was nearly as effective as DM alone when incubated in vitro with KLN-205 cells and much more effective in vivo than DM alone. Control immunoconjugates were ineffective. Finally, while the free 174H.64 MAb produced a significant increased time of survival of mice bearing KLN-205 metastases, a much greater survival was found with mice treated with the 174H.64-DM immunoconjugate with some mice apparently demonstrating long term survival (>100 days). We conclude that MAb 174H.64 may have potential therapeutic benefit against Sq Ca.

Materials and Methods

Experimental animals: DBA/2 male mice, 8-12 weeks of age, were obtained from the Medical Sciences Animal Centre, University of Alberta.

Cell lines: A murine Sq Ca line, KLN-205 (Kaneko, et al., 1978), a murine leukemia cell line, SL2R5, Wolcsin, et al., Int. J. Cancer, 23:519 (1979), and a human myeloid leukemia line, HL60-2, Gallagher, et al., Blood, 54:713 (1979),

- 29 -

were obtained from the American Type Culture Collection, Rockville, MD. All cell lines were maintained in RPMI 1640 medium supplemented with 10% FCS. KLN-205 is a murine lung Sq Ca cell line which metastasizes to the lung following i.v. injection. Kaneko, et al., *Cancer Res.*, 28:2084 (1978). The resulting lung metastases reacted with MAb 174H.64, demonstrating selective reactivity with the growing cells in the periphery of each tumor. Samuel, et al., *Cancer Res.*, 49:2465 (1989); Williams, et al., *J. Nat. Canc. Inst.* 51:1513 (1973).

Preparation of immunoconjugates: Immunoconjugates have been made in which the cytotoxic component was daunomycin (DM) attached to the target-specific conjugand via the acid-sensitive cis-aconityl spacer (CA). Shen, et al., *Biochem. Biophys. Res. Comm.*, 102:1048 (1981). These daunomycin immunoconjugates showed high specific cytotoxicity on target cells and could be used for purging tumor cells and functional T cells from bone marrow. The present study was designed to test the potential of MAb 174H.64-daunomycin immunoconjugates to target therapy to KLN-205 Sq Ca lung tumors. Immunoconjugates were prepared as described, Diener, et al., in *Antibody-Mediated Delivery System*, p. 1 (Marcel Dekker, Inc., N.Y. 1988) and Xie, et al., *Transplantation*, 44:770 (1987), according to the method of Shen, et al. (1981). MAbs were obtained from ascites fluids which were subjected to protein precipitation with 40%  $(\text{NH}_4)_2\text{SO}_4$  followed by dialysis against phosphate buffered saline at 4°C for 24 hours. This protein fraction was further purified by affinity chromatography on a protein A-sepharose column (Pharmacia). Daunomycin and cis-aconitic anhydride were purchased from Sigma Chemical Co., St. Louis, MO. Purified monoclonal antibody 174H.64 was obtained as described above. MAb anti-Thy1.2 was obtained from NEN and MAb 86H.1 which reacts against human myeloid cells, See Janowska-Wieczorek, et al., in *Leukocyte*



- 30 -

Typing II, Vol. 3, Human Myeloid and Hematopoietic Cells, p. 171 (Springer Verlag, N.Y. 1986), including HL-60 cells, was made in our laboratories.

Treatment of cells with cytotoxic immunoconjugates or other agents: Cells in phosphate-buffered saline (PBS) were treated with the immunoconjugates or other agents for 2 1/2 hours on ice. Thereafter the cells were washed 3 times and injected intravenously into recipient mice, or incubated for 24 hours at 37°C after which <sup>3</sup>H-thymidine incorporation by the cells was measured.

<sup>3</sup>H-thymidine incorporation: Cell cultures were pulsed for four hours with 0.5 μCi/well of <sup>3</sup>H-thymidine (specific activity 2.0 μCi/mmol) (NEN). Cells were harvested onto glass fibers with a Titertek semi-automated multiple sample collector (Flow Laboratories, Mississauga, Ontario). Thymidine incorporation was determined by liquid scintillation spectrometry.

Squamous carcinoma animal model: As described previously (Samuel, et al., 1989) using KLN-205 cells (Kaneko, et al., 1978).

<sup>125</sup>I-IUDR uptake: Mice were injected with 2 μCi/each of <sup>125</sup>I-IUDR (Edmonton Radiopharmaceutical Centre, Edmonton, Alberta, Canada) and 4 hours later, the lungs were removed, cut into small pieces, washed with 10% trichloroacetic acid (TCA) 3 times for three days and assessed for radioactivity content using a gamma-counter.

Statistical analysis: Most data were assessed by Student's t-test. Survival data were assessed by modified Wilcoxon.

- 31 -

Results

Inhibition of in vitro proliferation of KLN-205 cells by MAb 174H.64-DM: We have previously described the selective reactivity of MAb 174H.64 with all mammalian Sq Ca tested including the KLN-205 murine lung squamous carcinoma cell line (Samuel, et al., 1989). To investigate the specific cytotoxicity of the immunoconjugate, the KLN-205 cell line, SL2R5 cell line and HL60-2 cell line were treated on ice for 2 hours with MAb 174H.64-DM, MAb 86H.1-DM, MAb anti Thy1.2-DM, free DM, MAb 174H.64, MAb anti-Thy1.2 or MAb 86H.1, and following washing, the cells were subsequently cultured for another 24 hours. Fig. 2 demonstrates the specificity of cell killing of the different antibodies in comparison with the daunomycin alone. While the HL-60 cells and SL2R5 cells were each inhibited by their respective MABs, only KLN-205 cells were inhibited by the MAb 174H.64-DM immunoconjugate. It is noteworthy that the inhibition in vitro of the proliferation of KLN-205 cells by the MAB 174H.64-DM immunoconjugate was nearly as effective as the daunomycin alone.

In vitro treatment of KLN-205 cells with MAb 174H.64-DM inhibits tumor cell proliferation in the lungs of i.v. injected mice: For this experiment we employed the  $^{125}\text{I}$ -IUDR uptake assay as a measure of KLN-205 tumor cell proliferation in the lungs. We first established that the uptake of  $^{125}\text{I}$ -IUDR in the lungs is directly proportional to the number of i.v. injected KLN-205 cells at least over the range of  $10^5$  to  $10^6$  cells (Fig. 3).

KLN-205 cells were then treated on ice for 2 hours with the MAb 174H.64-DM immunoconjugate or with various controls, including PBS, MAb 174H.64 alone or free DM. Thereafter cells were washed three times and injected into DBA/2 mice ( $10^6$  cells/mouse). On the 23rd day after injection, tumor growth in the lung was monitored using  $^{125}\text{I}$ -IUDR uptake.

- 32 -

Results in Fig. 4 show that the MAb 174H.64-DM pretreatment significantly reduced the growth of lung tumors approximately 85% and was as effective as incubation of the cells with DM alone (Fig. 4).

I.V. injected MAb 174H.64-DM inhibits the growth of established lung metastatic KLN-205 cells in vivo: The purpose of this experiment was to investigate the specific cytotoxicity of MAb 174H.64-DM in vivo.  $10^6$  KLN-205 cells were injected i.v. into DBA/2 mice. Three days later MAb 174H.64-DM was injected i.v. every second day for 10 days (5 injections). On the 23rd day after injection of the tumor cells, tumor growth was measured by assessing  $^{125}\text{I}$ -IUDR uptake in the lungs. The results in Fig. 5 show that MAb 174H.64-DM significantly ( $p < 0.001$ ) reduced  $^{125}\text{I}$ -IUDR uptake by about 80% while MAb 86H.1-DM had no significant effect. Daunomycin alone had a slight, but insignificant effect but MAb 174H.64 alone reduced the tumor cell proliferation approximately 42% ( $P < 0.001$ ).

Survival of mice receiving MAb 174H.64-DM Therapy: The above experiment was repeated but instead of sacrificing the mice to monitor the growth of KLN-205 cells in the lungs, the mice were simply monitored for survival. The results in Fig. 2 show that MAb 174H.64-DM treated mice survived significantly longer ( $p < 0.001$ ) than untreated or antibody treated mice. MAb 174H.64 alone also improved the survival of tumor bearing mice ( $P < 0.001$ ).

### Discussion

The present study was designed to test the hypothesis that a MAb directed against the proliferative (STEM) cell compartment of squamous carcinomas has therapeutic potential. We have used a novel MAb, 174H.64 which appears to detect a unique epitope on cytoskeletal proteins which may serve as a marker for the stem cell population in normal stratified squamous epithelia and squamous carcinomas (Samuel, et al., 1981). MAb 174H.64 reacts with all Sq Ca tested regardless of

- 33 -

histological origin (Idem.) as well as with all Sq Ca of all mammals tested, including those of humans (>62 tested), dogs (10 tested), cattle (40 tested) and cats (2 tested). In the present study we took advantage of its reactivity with a murine metastatic lung Sq Ca, KLN-205, to develop an animal model for chemoimmunotherapy with a daunomycin conjugate of MAb 174H.64 (MAb 174H.64-DM). Previous studies using the KLN-205 cell line have shown that the tumor periphery of the lung metastatic nodules is composed of highly proliferative cells which are the progenitors of the more differentiated cells in the central portion of the tumor. We have shown that MAb 174H.64 selectively stains the peripheral layer of KLN-205 lung tumors as well as human and bovine Sq Ca. This provided the rationale for using the KLN-205 model to attempt to selectively target therapy to the "stem" cells of the tumor as it might be expected that the internal, more differentiated cells are no longer capable of neoplastic proliferation.

We chose daunomycin as the cytotoxic component of the immunoconjugate because of our extensive experience with this drug. Diener, et al., Science, 231:148 (1986); Diener, et al., in Cellular Basis of Immune Modulation, p. 509 (Alan R. Liss, Inc., NY 1988); Diener, et al. (1988) (Marcel Dekker); Xie, et al. (1987). We have previously shown that an immunoconjugate of anti-Thy1.2 MAb and daunomycin possesses high specific cytotoxicity for target cells and could be used for the specific purging of Thy1.2+ tumor cells and murine functional T cells from the bone marrow. We have discovered that an immunoconjugate of MAb 174H.64 with daunomycin also produces marked, specific inhibition of the growth of KLN-205 murine squamous carcinoma both in vitro and in vivo when compared to irrelevant conjugates, free monoclonal antibodies, or free daunomycin.

Our first experiments were designed to demonstrate the specificity of the immunoconjugate killing in vitro. For this we conducted a criss-cross experiment with three cell

- 34 -

lines and three immunoconjugates which, based on immunofluorescent and/or immunoenzyme testing should be specific for their specific cell lines. Exquisite specificity and excellent killing was noted in each case: MAb86H.1-DM killed only HL-60 cells, MAb anti-Thy1.2-DM killed only SL2-R5 cells and MAb 174H.64 killed only KLN-205 cells. Interestingly, the killing of KLN-205 cells by the 174H.64 immunoconjugate was nearly as effective as the free daunomycin added to the culture.

An extension of the in vitro experiment was then performed whereby the KLN-205 cells were incubated in vitro with the immunoconjugate, free antibody or daunomycin, washed, injected i.v., and the metastatic growth in the lungs monitored. In this case a marked reduction of the metastatic growth of the KLN-205 cells in the lungs was achieved by preincubation with the MAb 174H.64-DM conjugate. Again the reduction achieved with the immunoconjugate was about the same as that achieved with free daunomycin. In vitro incubation with the unconjugated MAb 174H.64 caused a slight but statistically non-significant reduction in growth of KLN-205 cells in the lungs.

The next two experiments were designed to directly test the in vivo therapeutic potential of the MAb-174H.64-DM immunoconjugate. Immunotherapy was started three days following the i.v. injection of  $10^6$  KLN-205 cells, at a time when the lung metastatic cells should have been well established (Kaneko, et al., 1981; Williams, et al., 1973). Five therapeutic injections of MAb-174H.64-DM were given i.v. every second day for ten days. Growth of the KLN-205 cells in the lungs was monitored at day 23 by using the  $^{125}\text{I}$ -IUDR uptake assay and survival was monitored for >100 days. The two estimates of the therapeutic potential of the various compounds gave very similar results. Mice injected with MAb 86H.1-DM showed no therapeutic benefit and showed similar tumor growth and survival as those injected with PBS. Daunomycin alone gave

- 35 -

a slight reduction of growth and a slight increase in survival. An even greater therapeutic benefit was achieved with unconjugated MAb 174H.64. However by far the best therapy was achieved following i.v. injection with the MAb 174H.64-DM immunoconjugate where an >80% reduction in tumor cell growth in the lungs and a prolonged survival was achieved. Greatly prolonged survival was achieved in 20% (5 mice) of the mice which survived >100 days. The therapeutic benefit of the 174H.64 immunoconjugate is even more impressive if one considers that the therapeutic regimen used in the present experiments may not be an optimal one.

The efficacy of MAb 174H.64-DM probably depends on the specificity of its binding to the target cell surface and the accumulation of the drug inside the target cells. Broxterman, et al., *Biochem. Pharmacol.*, 37:2389 (1988); Dillman, et al., *Cancer Res.*, 48:6097 (1988); Pimm, et al., *Cancer Immunol. Immunother.*, 27:267 (1988). Pimm and coworkers have studied human tumors growing in nude mice injected with daunomycin immunoconjugates. They found that the tumors showed localization of both the drug and antibody and at the time of analysis (3 days after injection), the tumor levels of daunomycin were over 100 times those seen in mice injected with free daunomycin. Following endocytosis of the immunoconjugate, the potentially cytotoxic component appears to regain full pharmacologic activity upon release from the acid-sensitive spacer in lysosomes (Dillman, et al. 1988). Those results are consistent with our observations that at the same daunomycin concentration the immunoconjugate MAb 174H.64-DM showed a marked suppression of the growth of KLN-205 cells in vivo while free daunomycin did not, although the free daunomycin showed the same or better cytotoxic potency as the immunoconjugate following in vitro incubation.

Gallego, et al. (1984) investigated four different linkage groups for coupling daunomycin to antibody. They found that conjugates made with a cis-aconityl linkage, which was the

- 36 -

same one used in the present work, displayed the greatest selective cytotoxicity against tumor cells. Our results appear to substantiate the efficacy of daunomycin immunoconjugate made with cis-aconityl linkage groups.

MAb 174H.64 appears to detect a novel epitope expressed on certain cytoskeletal proteins expressed only in the stem cell populations of normal and neoplastic stratified squamous epithelium. The present experiments as well as our previous observations suggest that the epitope detected by MAb 174H.64 is also expressed on the surface of the KLN-205 cells. Other cell surface determinants have been reported for some cytoskeletal proteins, see Diaz, et al., J. Invest. Dermatol., 89:287 (1987); Zimmerman, et al., J. Cell. Biol., 95:237a (1982). As the 174H.64 epitope may also be present on the surface of the basal cells of stratified squamous epithelium some skin toxicity might have been expected in the present experiments. However, we have never seen any evidence of any skin lesions nor any other obvious gross pathology in over 100 mice which have received multiple injections of either the free 174H.64 MAb or the MAb 174H.64-DM conjugate including our long term (>100 day) survivors.

Based on our studies in mice we conclude that MAb 174H.64 may have promising therapeutic potential in Patients with squamous cell carcinoma. In our preliminary radioimmunoimaging studies with radiolabeled MAb 174H.64 excellent in vivo localization of this MAb in human squamous cancer was observed.

- 37 -

Example 3:      Immunoimaging Using MAb 174H.64

Clinical Utility of MAb 174H.64

To test the clinical usefulness of radiolabeled MAb 174H.64 as an in vivo tumor localizing agent the purified whole antibody was labeled with Technetium-99m and injected in a number of patients bearing squamous cell carcinomas.

The labeling procedure was as follows:

A mixture of Sodium Potassium Tartarate (0.282 g) and Potassium Phthalate (0.817 g) was dissolved in 100 ml sterile water for injection in a pyrogen-free beaker with constant stirring (the "buffer solution"). The solution was purged with dry, particle-free nitrogen for 30 min. The nitrogen source was previously passed through a nitrogen purifier to remove trace amounts of oxygen and then filtered through a 0.02 $\mu$  filter to remove any residual particulate contaminants. A stannous chloride solution was then prepared by dissolving 1.896 g of anhydrous stannous chloride in 20 ml of concentrated hydrochloric acid to make a 0.5M SnCl<sub>2</sub> solution. One milliliter of the stannous solution was added immediately to the previously prepared buffer solution and the pH of this final mixture was adjusted carefully to 5.6 $\pm$  0.05 with 10 N sodium hydroxide solution. The mixture was purged with nitrogen gas and filtered through a 0.22 $\mu$  filter. This is called the reducing solution. One milliliter of MAb 174H.64 solution in phosphate buffer was then mixed with 0.67 ml of filtered reducing solution and the final MAb concentration was adjusted such that the mixture contained 1 mg antibody/ml. After mixing, the vial containing the antibody and reducing solution was purged with nitrogen for several minutes and kept under a nitrogen atmosphere at room temperature for 21 hours. After the incubation period, the treated antibody solution was filtered through a 0.22 $\mu$  filter. The latter filtrate was assayed for its protein content, for pyrogens, for purity (using size exclusion column chromatography) and for immunoreactivity. No differences were observed between the original untreated whole antibody and the derivatized one



- 38 -

either in terms of immunoreactivity or molecular weight. The solution of prepared antibody was then frozen until ready for use clinically. At the time of use, the vial containing the frozen reduced antibody is thawed at room temperature and the required amount of TC-<sup>99m</sup> sodium pertechnetate solution (up to 50 mCi) were added and the mixture allowed to incubate for 1 hour at room temperature. At the end of the incubation period, a sample of the mixture was tested for any unbound TC-<sup>99m</sup> by thick layer chromatography using acetone as a developing solvent. Radiolabeling efficiency was greater than 95%.

#### Clinical Results

A clinical study involving 11 patients with metastatic squamous cell carcinoma of the head and neck, cervix, and lung was conducted to evaluate the uptake of <sup>99m</sup>Tc-labeled MAb 174H.64 after intravenous injection into these patients. An antibody dose of 2 mg (about 50 mCi) was diluted with 100 ml normal saline and infused over 30 minutes. Any abnormal uptake was measured by planar and single photon emission computerized tomography at various intervals after the injection. Results obtained within 24 hours indicated that two patients showed an apparent negative uptake while 9 patients were shown to be truly positive. Figure 7 illustrates such a scan observed for a patient with cervical squamous cell carcinoma whose tumor had metastasized to the upper chest region. It demonstrates the uptake of the antibody in a lesion estimated at 2-4 mm in diameter (see Fig. 7)

We found it to be unusual that the pharmacokinetics of a labeled whole antibody is indeed similar to the known behaviour of a fragment. Blood clearance was expeditious and uptake could be seen as early as 3 hours after injection. Analysis of the radioactivity in the patient's urine has demonstrated that the secreted radioactivity was not due to free pertechnetate, but rather due to bound radioactivity.

- 39 -

## CLAIMS

1. A antibody preparation comprising an antibody which essentially only binds to antigens associated with squamous cell carcinoma and stem cell populations of stratified epithelium.
2. The antibody preparation of claim 1 wherein said antigens include cytoskeletal proteins having molecular weights of approximately 48 to 50kD and 57kD.
3. The antibody preparation of claim 1 wherein squamous cell carcinoma specific reactivity extends to spontaneous tumors of non-human mammals.
4. The antibody preparation of claim 1 wherein said antibody preferentially reacts towards a proliferative compartment of said human squamous cell carcinoma.
5. The antibody preparation of claim 1 wherein said antibody preferentially reacts with basal and parabasal mature squamous epithelium.
6. The antibody preparation of claim 5 wherein said mature squamous epithelium is human cervical squamous metaplasia.
7. The antibody preparation of claim 1, said preparation being derived from an antibody which is secreted by a hybridoma having ATCC deposit number HB 10105 or a reclone thereof.
8. The antibody preparation of claim 1, said preparation comprising a labelled antibody or binding fragment thereof.

- 40 -

9. A therapeutic agent comprising an antibody which selectively binds to antigens associated with human squamous cell carcinoma and stem cell populations of stratified epithelium, said antigens including cytoskeletal proteins having molecular weights of approximately 48 to 50 kD and 57 kD, said antibody being associated with a cytotoxic agent, said antibody essentially retaining its specificity.

10. A method of localizing a squamous cell carcinoma which comprises:

administering a radiolabelled monoclonal antibody preparation according to claim 1 to a patient; and  
determining a location of said squamous cell carcinoma by immunoimaging of said radiolabeled monoclonal antibody.

11. The method of claim 10 wherein said monoclonal antibody is secreted by a hybridoma having ATCC deposit number HB 10105 or a derivative thereof.

12. A method of treating squamous cell carcinoma which comprises:

administering a therapeutically effective dose to a cancer patient under conditions permitting binding of a monoclonal antibody preparation according to claim 1, said monoclonal antibody being associated with a cytotoxic agent, said monoclonal antibody essentially retaining its specificity.

13. The method of claim 11 wherein said monoclonal antibody is secreted by a hybridoma having ATCC deposit number HB 10105 or a reclone thereof.

14. A method for detecting the presence of a squamous cell carcinoma associated antigen in a sample which comprises incubating a monoclonal antibody preparation

- 41 -

according to claim 1 with said sample for a period of time sufficient to permit at least some of the antibody to bind to said antigen and detecting the bound antibody.

15. The method of claim 11 wherein said monoclonal antibody is secreted by a hybridoma having ATCC deposit number HB 10105 or a reclone thereof.

16. A monoclonal antibody which essentially only binds, to antigens associated with human squamous cell carcinoma and stem cell populations of stratified epithelium, said antigens include cytoskeletal proteins having molecular weights of approximately 48 to 50kD and 57kD, said monoclonal antibody preferentially reacting with a proliferative compartment of said human squamous cell carcinoma.

17. The monoclonal antibody of claim 16 wherein said monoclonal antibody preferentially reacts with basal and parabasal mature squamous epithelium.

18. The monoclonal antibody of claim 17 wherein said mature squamous epithelium is human cervical squamous metaplasia.

19. An antibody preparation comprising an antibody which preferentially binds to antigens associated with human squamous cell carcinoma and stem cell populations of stratified epithelium, said antigens being selected from the group consisting of cytoskeletal proteins having molecular weights of approximately 48 to 50 kD and 57 kD.

20. An antibody preparation of claim 1, wherein said monoclonal antibody selectively reacts with thymic epithelium and myoepithelial cells of human breast ducts.

21. An antibody preparation of claim 19 which reacts with squamous cells carcinomas of cows, dogs, or cats.

22. An antibody preparation of claim 19 comprising a preparation of antigen-binding fragments or antibody conjugates which bind to human squamous cell carcinoma and stem cell populations of stratified epithelium, said antigens having molecular weights of approximately 48 to 50 kD and 57 kD.

23. A radiolabelled antibody preparation according to claim 18.

24. The radiolabelled antibody preparation according to claim 31 wherein said radiolabelled antibody includes a radionuclide selected from the group consisting of  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{90}\text{Y}$ ,  $^{211}\text{At}$ ,  $^{67}\text{Cu}$ ,  $^{186}\text{Re}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{111}\text{In}$ , and  $^{67}\text{Ga}$ .

25. An enzyme labelled antibody preparation of claim 8.

26. A drug conjugated antibody preparation of claim 1.

27. A process of isolating antigens comprising immobilizing an antibody preparation of claim 1 on a solid support, contacting said solid support with a biological sample, separating unbound impurities from the solid support, and eluting the antigen in a purified form from the immobilized antibody preparation.

28. A process according to claim 27 comprising immobilizing 174H.64 on a solid support, contacting said solid support with a biological sample, separating unbound impurities from the solid support, and eluting the antigen in an isolated form from the immobilized 174H.64 preparation.

- 43 -

29. A method of diagnosing squamous cell carcinoma which comprises detection or quantification of the binding reaction of the antibody preparation of claim 1 and its reaction partner.

30. A method of claim 29 wherein the reaction detected or quantified occurs in vivo.

31. Use of an antibody preparation according to claim 1 in the manufacture of a composition for the diagnosis or therapy of squamous cell carcinoma.

32. The therapeutic agent of claim 9 wherein the cytotoxic agent is daunomycin.


33. The therapeutic agent of claim 9 wherein the cytotoxic agent is associated with the antibody by an acid-sensitive cis-aconityl spacer.

*FIG. 1.*



**FIG. 2.**


**IN VITRO TREATMENT**





3/7


**FIG. 3.**



4/7


# FIG. 4.

## IN VITRO INCUBATION




5/7

**FIG. 5.**




**FIG. 6.**

**THE EFFECT OF MAB174H.64-DM ON THE SURVIVAL OF TUMOR-BEARING MICE**



7/7

**FIG. 7.**




THORAX POST  
24 HRS

LYMPH NODE MET RIGHT LUNG HILUS  
PRIMARY TUMOR CERVIX CARCINOMA

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/02152

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>5</sup> : C 12 P 21/08, A 61 K 39/395, G 01 N 33/574, 33/577, 33/68		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup>	C 12 P, A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	BIOSIS, AN no. 88.477505 J. Samuel et al.: "Novel squamous cell carcinoma differentiation antigens recognized by MAb 174H.64", see abstract T115 & 17th Annual UCLA (University of California-Los Angeles) Symposia on Molecular and cellular Biology, Keystone, Colorado, USA, April 23-30, 1988, J. Cell Biochem. 0 (12 Part E), 1988, 132	1-9, 14, 16-23, 25- 29, 31-33
X	--- Differentiation, volume 31, 1986, Springer-Verlag, (Berlin, DE), M. Huszar et al.: "Monoclonal antibodies to various acidic (type I) cytokeratins of stratified epithelia", pages 141-153 see the whole article	1, 4-6, 8, 14, 20, 25, 29, 31
X	--- Cancer Research, volume 47, no. 12, 15 June 1987, (Philadelphia, PA, US), D.A. Johnson et al.: "Antitumor ./.	1, 4, 8, 14, 25, 26, 29, 31
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
21st September 1990	12. 10. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	R.J. Eernisse 	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	<p>xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D", pages 3118-3122 see the whole article</p> <p>--</p>	
P,X	<p>Cancer Research, volume 49, no. 9, 1 May 1989, (Philadelphia, PA, US), J. Samuel et al.: "A novel marker for basal (Stem) cells of mammalian stratified squamous epithelia and squamous cell carcinomas", pages 2465-2470 see the whole article</p> <p>-----</p>	<p>1-9,14,16- 23,25-29, 31-33</p>

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V.  OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1.  Claim numbers .....\* because they relate to subject matter not required to be searched by this Authority, namely:

\* Claims 10-13, 15, 24, 30

See PCT-Rule 39.1 (iv) methods for treatment of the human or animal body by surgery or therapy as well as diagnostic methods

2.  Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.  Claim numbers ..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(e).

VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- The additional search fees were accompanied by applicant's protest.  
 No protest accompanied the payment of additional search fees.



# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>SMW/CP5635370</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 97/ 02108</b>	International filing date (day/month/year) <b>05/08/1997</b>	(Earliest) Priority Date (day/month/year) <b>05/08/1996</b>
Applicant <b>QUANTUM BIOSYSTEMS LTD. et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 2 sheets.  
 It is also accompanied by a copy of each prior art document cited in this report.

1.  Certain claims were found unsearchable (see Box I).
2.  Unity of invention is lacking (see Box II).
3.  The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing
  - filed with the international application.
  - furnished by the applicant separately from the international application,
    - but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
  - Transcribed by this Authority
4. With regard to the title,
  - the text is approved as submitted by the applicant.
  - the text has been established by this Authority to read as follows:
5. With regard to the abstract,
  - the text is approved as submitted by the applicant.
  - the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:
 

Figure No.     -      as suggested by the applicant.  None of the figures.

  - because the applicant failed to suggest a figure.
  - because this figure better characterizes the invention.

**INTERNATIONAL SEARCH REPORT**

International Application No  
PCT/GB 97/02108

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 G01N33/574 C07K16/30 G01N33/577

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 G01N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 215 046 A (UNIVERSITY OF DUNDEE) 13 September 1989 see table 1	1,2
A		3-8
X	--- P.R. PROSPERI ET AL.: "Diagnosis of carcinoma of the uterine cervix with monoclonal antibodies technique" PATOL CLIN OSTET GINECOL, vol. 14, no. 5, 1986, ROME IT, pages 348-355, XP002046427 see the whole document	1,2
A	-----	3-8

Further documents are listed in the continuation of box C.       Patent family members are listed in annex.

- ° Special categories of cited documents :
- \*A\* document defining the general state of the art which is not considered to be of particular relevance
  - \*E\* earlier document but published on or after the international filing date
  - \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - \*O\* document referring to an oral disclosure, use, exhibition or other means
  - \*P\* document published prior to the international filing date but later than the priority date claimed
  - \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
  - \* & \* document member of the same patent family

Date of the actual completion of the international search  17 November 1997	Date of mailing of the international search report  21. 11. 97
---	--

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Van Bohemen, C
--	--

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02108

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2215046 A	13-09-89	NONE	
-----			

RECORDS ENTERED .....  
 RECORDS SEEN .....  
 DIARY ENTRY .....  
 RENEWAL ENTERED X .....  
 ALREADY ENTERED .....

PATENT COOPERATION TREATY

09/230985 # 6 attach  
 copy sent to ESK

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING  
 OF A CHANGE

(PCT Rule 92bis.1 and  
 Administrative Instructions, Section 422)

To:

WALTON, Seán, M.  
 Mewburn Ellis  
 York House  
 23 Kingsway  
 London WC2B 6HP  
 ROYAUME-UNI

RECEIVED  
 - 5 MAY 1998

Date of mailing (day/month/year) 24 April 1998 (24.04.98)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference SMW/CP5635370	
International application No. PCT/GB97/02108	International filing date (day/month/year) 05 August 1997 (05.08.97)

1. The following indications appeared on record concerning:

the applicant       the inventor       the agent       the common representative

Name and Address

QUANTUM BIOSYSTEMS LTD.  
 12 Pembroke Avenue  
 Denny Industrial Centre  
 Waterbeach  
 Cambridge CB5 9PB  
 United Kingdom

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

the person       the name       the address       the nationality       the residence

Name and Address

QUANTUM BIOSYSTEMS LTD., in  
 Creditors' Voluntary Liquidation,  
 acting by its liquidator, ROGER  
 WILLIAM GILLET of CRANE & PARTNERS  
 Rutland House  
 44 Masons Hill  
 Bromley, Kent BR2 9EQ  
 United Kingdom

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

the receiving Office       the designated Offices concerned  
 the International Searching Authority       the elected Offices concerned  
 the International Preliminary Examining Authority       other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Eugénia Santos
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 258.83.38

# INTERNATIONAL SEARCH REPORT

Intern. Application No.  
PCT/GB 97/02108

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 G01N33/574 C07K16/30 G01N33/577

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 G01N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 215 046 A (UNIVERSITY OF DUNDEE) 13 September 1989 see table 1	1,2
A	---	3-8
X	P.R. PROSPERI ET AL.: "Diagnosis of carcinoma of the uterine cervix with monoclonal antibodies technique" PATOL CLIN OSTET GINECOL, vol. 14, no. 5, 1986, ROME IT, pages 348-355; XP002046427 see the whole document	1,2
A	-----	3-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

17 November 1997

Date of mailing of the international search report

21. 11. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Bohemen, C

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/GB 97/02108

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2215046 A	13-09-89	NONE	



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>G01N 33/574, C07K 16/30, G01N 33/577</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/05967</b> <b>(43) International Publication Date:</b> 12 February 1998 (12.02.98)
<p><b>(21) International Application Number:</b> PCT/GB97/02108</p> <p><b>(22) International Filing Date:</b> 5 August 1997 (05.08.97)</p> <p><b>(30) Priority Data:</b>  9616429.8                      5 August 1996 (05.08.96)                      GB</p> <p><b>(71) Applicant (for all designated States except US):</b> QUANTUM BIOSYSTEMS LTD. [GB/GB]; 12 Pembroke Avenue, Denny Industrial Centre, Waterbeach, Cambridge CB5 9PB (GB).</p> <p><b>(72) Inventors; and</b></p> <p><b>(75) Inventors/Applicants (for US only):</b> MASON, Robert, James [GB/GB]; New Chapter, 4 Park Road, Cheveley, Newmarket, Suffolk CB8 9DF (GB). PASCOE, Edward, William [GB/GB]; 23 Main Street, Wardy Hill, Ely, Cambridgeshire CB9 4NX (GB). HOLMES, Christopher, Harold [GB/GB]; University of Bristol, Dept. of Obstetrics &amp; Gynaecology, St. Michael's Hospital, Southwell Street, Bristol BS2 8EG (GB).</p> <p><b>(74) Agents:</b> WALTON, Seán, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).</p>		<p><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>With international search report.</i></p>
<b>(54) Title:</b> ASSESSMENT OF CERVICAL CELLS		
<p><b>(57) Abstract</b></p> <p>A method of determining abnormality in a tissue sample containing cells of the cervix, the method comprising determining binding of specific binding substances to the sample and comparing the binding with the pattern of binding of said specific binding substances to a normal cervical cell sample. The specific binding substances may be antibodies. Hybridomas which produce suitable antibodies have been deposited at the European Collection of Animal Cell Cultures (ECACC), Centre for Applied Microbiology &amp; Research, Salisbury, Wiltshire SP4 0JG, United Kingdom on 6 February 1995 under the accession numbers ECACC 95020718, 95020716, 95020720, 95020717 and 95020719.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

**NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES**

(PCT Rule 47.1(c), first sentence)

To:

WALTON, Seán, M.  
Mewburn Ellis  
York House  
23 Kingsway  
London WC2B 6HP  
ROYAUME-UNI



Date of mailing (day/month/year) 12 February 1998 (12.02.98)		<b>IMPORTANT NOTICE</b>	
Applicant's or agent's file reference SMW/CP5635370			
International application No. PCT/GB97/02108	International filing date (day/month/year) 05 August 1997 (05.08.97)	Priority date (day/month/year) 05 August 1996 (05.08.96)	
Applicant QUANTUM BIOSYSTEMS LTD. et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU, BR, CA, CN, EP, IL, JP, KP, KR, NO, PL, SK, US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:  
AL, AM, AP, AT, AZ, BA, BB, BG, BY, CH, CU, CZ, DE, DK, EA, EE, ES, FI, GB, GE, GH, HU, IS, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, OA, PT, RO, RU, SD, SE, SG, SI, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW  
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 12 February 1998 (12.02.98) under No. WO 98/05967

**REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)**

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

**REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))**

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p>	<p>Authorized officer  J. Zahra</p>
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

PATENT COOPERATION TREATY

RECD 02 OCT 1998  
WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SMW/CP5635370	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)
International application No. PCT/GB97/02108	International filing date (day/month/year) 05/08/1997	Priority date (day/month/year) 05/08/1996	
International Patent Classification (IPC) or national classification and IPC G01N33/574			
Applicant QUANTUM BIOSYSTEMS LTD., in Creditors...et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of    sheets.

3. This report contains indications relating to the following items:

- I    Basis of the report
- II    Priority
- III    Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV    Lack of unity of invention
- V    Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI    Certain documents cited
- VII    Certain defects in the international application
- VIII    Certain observations on the international application

Date of submission of the demand 04/03/1998	Date of completion of this report 30. 09. 98
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer Wallinder, E Telephone No. (+49-89) 2399-8435 

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB97/02108

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-55 as originally filed

**Claims, No.:**

1-9 as originally filed

2. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:

3.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims 3, 5-7, 9/partly/
	No:	Claims 1, 2, 4, 8, 9/partly/
Inventive step (IS)	Yes:	Claims 3, 5-7, 9/partly/
	No:	Claims 1, 2, 4, 8, 9/partly/
Industrial applicability (IA)	Yes:	Claims 1-9
	No:	Claims

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB97/02108

---

2. Citations and explanations

**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**Ad Section V.**

- 1). Reference is made to the following documents:

D1 = GB-A-2 215 046

D2 = PATOL. CLIN. OSTET GINECOL., Vol. 14., No. 5, 1986; ROME IT, pages 348-355;

P.R. PROSPERI ET AL.: "Diagnosis of carcinoma of the uterine cervix with monoclonal antibodies technique".

- 2). It would appear that the broad scope of Claims 1 and 2 are anticipated by the disclosures in D1 and D2. Thus, references are made to D1, Table 1 and Claims; and to D2, the abstract.

Therefore, the subject-matter of Claims 1 and 2 lacks novelty and inventive step. The subject-matter of Claims 1 and 2 does not meet the requirements of Articles 33(2) and 33(3) PCT.

- 3). It would appear that the subject-matter of Claims 3, 5 to 7 and that part of Claim 9 referring to Claim 7 is novel and inventive over the cited prior art.

Thus, it is assumed that the deposited hybridomas as featured in these Claims meet the requirements as set out in Rule 13<sup>bis</sup> PCT. Thereby, the hybridomas' early deposition date of 06/02/1995, if compared with the priority date of 05/08/1996 of the present application, has been observed.

In view of this, the subject-matter of said Claims 3, 5 to 7 and 9 (partly) would appear to meet the requirements of Articles 33(2) and 33(3) PCT.

- 4). With regard to subject-matter of Claims 4, 8 and that part of a corrected Claim 9, referring to Claim 8 (see beneath under Section VIII, point 8), including the feature "specific binding substances include one or more such substances **which compete for binding to cervical tissue with one or more antibodies obtainable from a hybridoma selected from the deposited hybridomas...**", following comments are made. It would appear that the antibodies known from D1 and D2 will **compete for binding to cervical tissue** with the antibodies obtained by the hybridomas as featured in Claims 3 and 5. It is to be noted that the competition is not only related to the competition of binding to an epitope of an

antigen. Therefore, the competing antibodies need not to cross react in order to fall under the cited feature of Claims 4 and 8. Also steric hindrance at the surface cervical tissue could contribute to competition of non-cross reacting antibodies. As far as the Applicant has not shown the opposite it is assumed that the antibodies as disclosed in D1 and D2 (at least to some degree) compete for binding to cervical tissue with the antibodies as produced by the presently featured hybridomas.

In view of this it is considered that the method of Claim 4, the specific binding substance of Claim 8 and the use of Claim 9 (partly) lacks novelty and inventive step over the disclosures in D1 and D2.

Thus, the subject-matter of Claims 4, 8 and 9 (partly) does not meet the requirements of Articles 33(2) and 33(3) PCT.

- 5). It would appear that all Claims 1 to 9 is industrially applicable. The subject-matter of Claims 1 to 9, therefore, would appear to meet the requirements of Article 33(4) PCT.

**Ad Section VII.**

- 6). It is informed that the EPO for example requires a deposit receipt or equivalent proof of the deposit of a microorganism in case such proof has not been filed before.
- 7). Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 and D2 are not mentioned in the description, nor are these documents identified therein.

**Ad Section VIII.**

- 8). It would appear that Claim 6 incorrectly refers to Claim 4 instead of referring to Claim 5;  
Claim 8 refers to Claim 6 instead of referring to Claim 7; and  
Claim 9 refers to Claim 6 and Claim 7 instead of referring to Claim 7 and Claim 8.

- 9). As referred to above under Section V the feature "specific binding substances include one or more such substances **which compete for binding to cervical tissue with one or more antibodies obtainable from a hybridoma selected from the deposited hybridomas...**" has a broad and vague interpretation. An objection to lack of clarity under Article 6 PCT will therefore also have to be raised to the Claims 4, 8 and 9 including this feature.
- Thus, not only binding substances, antibodies, cross-reacting with the antibodies of the hybridomas as presently featured would appear to fall under the cited featured (see above under Section V).

# INTERNATIONAL SEARCH REPORT

Intern. Appl. No.  
PCT/GB 97/02108

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 G01N33/574 C07K16/30 G01N33/577

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 G01N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 215 046 A (UNIVERSITY OF DUNDEE) 13 September 1989 see table 1	1,2
A	---	3-8
X	P.R. PROSPERI ET AL.: "Diagnosis of carcinoma of the uterine cervix with monoclonal antibodies technique" PATOL CLIN OSTET GINECOL, vol. 14, no. 5, 1986, ROME IT, pages 348-355, XP002046427 see the whole document	1,2
A	-----	3-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

17 November 1997

Date of mailing of the international search report

21. 11. 97

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer  
  
Van Bohemen, C



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/GB 97/02108

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2215046 A	13-09-89	NONE	